The reduction of lymphocyte egress is a hallmark of the mechanism of drugs targeting the Sphingosine 1 phosphate receptors (S1PRs) like fingolimod (FTY720), an oral drug currently used for the treatment of relapsing-remitting multiple sclerosis [40]. Here, S1PR1 is linked to relapsing-remitting multiple sclerosis.